WJ-MSCs, cells at the heart of StemInov's innovation, are a particular type of adult MSC, of which several types have been described according to their location in the body and their origin in foetal (Wharton's jelly) or adult tissues (two main sources are bone marrow (BM), adipose tissue (AT)).
Thanks to their properties (figure below) Mesenchymal stem cells (MSCs) are a critical raw material for many regenerative medicine products, including cell-based therapies, engineered tissues, or combination products. Indeed, MSCs modulate the host immune systems, e.g., by secreting various trophic factors. Thereby, they reduce inflammation, promote neoangiogenesis, and prevent apoptosis and fibrosis. Additionally, they stimulate local stem cells to develop new tissue.
Furthermore, as they do not express major histocompatibility complex (MHC) class II molecules and have only low levels of MHC class I, MSCs are poorly immunogenic cells and therefore potentially usable in an allogeneic situation (where the donor is a different person from the patient), which makes them particularly attractive for clinical use.
Bioprocess Development for Human Mesenchymal Stem Cell Therapy Products, Jan Barekzai and al., 2019
WJ-MSCs have intrinsic properties that hold great promise for the treatment of infectious and inflammatory diseases, including septic shock. Indeed, these cells have a triple mechanism of action:
Unique modulation of immunity and inflammation through pro- or anti-inflammatory behavior depending on the environment in which they are located,
Direct and indirect antibacterial by effect on phagocytic cells capable of eliminating the pathogenic microorganisms responsible for the infection,
Targeting and migrating to injured sites for tissue repair.
ADVANTAGES OF WHARTON JELLY MSCs
COMPARED TO ADULT MSCs
THERAPEUTIC EFFECTIVENESS AND TOLERANCE OF FETAL SOURCE
NON LIMITED & NON INVASIVE SOURCING
BETTER HOMOGENEITY OF BATCHES
HIGHER PERFORMANCE AND LOWER COSTS